Search research articles
Contact Us
Filters
Showing results (91-100 of 112) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
Mark Agulnik, Gilda da Cunha Santos, David Hedley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 30, 2009
Occult primary
David S Ettinger, Mark Agulnik, Mihaela Cristea, et al.
Lancet (London, England)
|
June 14, 2016
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D Tap, Robin L Jones, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2011
NCCN Clinical Practice Guidelines Occult primary
David S Ettinger, Mark Agulnik, Justin M M Cates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
The Oncologist
|
October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 112) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
Mark Agulnik, Gilda da Cunha Santos, David Hedley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 30, 2009
Occult primary
David S Ettinger, Mark Agulnik, Mihaela Cristea, et al.
Lancet (London, England)
|
June 14, 2016
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D Tap, Robin L Jones, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2011
NCCN Clinical Practice Guidelines Occult primary
David S Ettinger, Mark Agulnik, Justin M M Cates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
The Oncologist
|
October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
The Lancet. Oncology
|
October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.
Page
of 12